Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases. [PDF]
, 2019 Denosumab has been used successfully to treat disease-associated osteoclast overactivity, including giant cell tumor of bone. Given its mechanism of action, denosumab is a potent potential treatment of other osteoclast bone dysplasias including central ...
Bernthal, Nicholas M +8 more
core +2 more sources
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]
, 2019 ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K +9 more
core +2 more sources
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study [PDF]
Endocrinology and Metabolism, 2023 Background Persistence with denosumab in male patients has not been adequately investigated, although poor denosumab persistence is associated with a significant risk of rebound vertebral fractures.
Chaiho Jeong +11 more
doaj +1 more source
SAT-512 Severe Hypocalcemia Presenting as Status Epilepticus after Denosumab Use in Metastatic Prostate Cancer [PDF]
, 2019 Introduction: Denosumab decreases the incidence of skeletal-related events in patients with metastatic bone disease and is used routinely as part of the therapeutic strategy for various cancers.
Aziz, Ammara, Saeed, Zeb
core +1 more source
Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]
, 2016 Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen +42 more
core +2 more sources
Effect of risedronate on bone loss at discontinuation of denosumab
Bone Reports, 2020 Purpose: The occurrence of multiple vertebral fractures was reported after denosumab discontinuation. The use of bisphosphonates following denosumab has been suggested to prevent this bone loss.
Michel Laroche +4 more
doaj +1 more source
Denosumab treatment in patients with different courses of osteoporosis
Остеопороз и остеопатии, 2017 We present three clinical cases of successful osteoporosis treatment with denosumab in patients with different courses of osteoporosis: postmenopausal with bisphosphonates ineffectiveness, osteoporosis of mixed etiology in patient on thyroid stimulating ...
Liudmila Ya. Rozhinskaya +4 more
doaj +1 more source
Frontiers in Endocrinology, 2020 Denosumab is a potent osteoclast inhibitor targeted to prevent osteoporotic bone loss and thereby reduce fractures in the aging population. Recently, an elevated risk of rebound fractures following denosumab discontinuation was identified, unless ...
Katharina Jähn-Rickert +7 more
doaj +1 more source
Current indications for denosumab in benign bone tumours
EFORT Open Reviews, 2023 Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation. Given its high efficacy, denosumab
Antal Imre +2 more
doaj +1 more source
The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention [PDF]
, 2018 Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients ...
Bedogni, Alberto +7 more
core +2 more sources